Lubna jamil Abdelhafez

Dr. Lubna jamil Abdelhafez


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2021 in Molecules
Verified
Journal Article
Open access
PDF file
KSKarema Mohamed Soliman
Karema Mohamed Soliman
GRGhada Mohamed Ragab
Ghada Mohamed Ragab
Ahmad SalahuddinAhmad Salahuddin
Ahmad Salahuddin
LALubna jamil Abdelhafez
Lubna jamil Abdelhafez
EAEkram Abd Al-Haleem
Ekram Abd Al-Haleem
Background: Alzheimer’s disease (AD) is a chronic neurological illness that causes considerable cognitive impairment. Hepatic and renal dysfunction may worsen AD by disrupting β-amyloid homeostasis at the periphery and by causing metabolic dysfunction. Wheatgrass (Triticum aestivum) has been shown to have antioxidant and anti-inflammatory properties. This work aims to study the effect of aluminum on neuronal cells, its consequences on the liver and kidneys, and the possible role of fluoxetine and wheatgrass juice in attenuating these pathological conditions. Method: Rats were divided into five groups. Control, AD (AlCl3), Fluoxetine (Fluoxetine and AlCl3), Wheatgrass (Wheatgrass and AlCl3), and combination group (fluoxetine, wheatgrass, and AlCl3). All groups were assigned daily to different treatments for five weeks. Conclusions: AlCl3 elevated liver and kidney enzymes, over-production of oxidative stress, and inflammatory markers. Besides, accumulation of tau protein and Aβ, the elevation of ACHE and GSK-3β, down-regulation of BDNF, and β–catenin expression in the brain. Histopathological examinations of the liver, kidney, and brain confirmed this toxicity, while treating AD groups with fluoxetine, wheatgrass, or a combination alleviates toxic insults. Conclusion: Fluoxetine and wheatgrass combination demonstrated a more significant neuroprotective impact in treating AD than fluoxetine alone and has protective effects on liver and kidney tissues.

12 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MAMarwa Ahmed Abd elhamid Ahmed
Marwa Ahmed Abd elhamid Ahmed
EMEman Mehanna
Eman Mehanna
NMNoha Mesbah
Noha Mesbah
Dina Abo-elmattyDina Abo-elmatty
Dina Abo-elmatty
LALubna jamil Abdelhafez
Lubna jamil Abdelhafez
MHMohamed M. Hafez
Mohamed M. Hafez
Background/Objectives: Pulmonary fibrosis is a chronic, progressive lung disease marked by scarring and inflammation, leading to impaired respiratory function. This study aimed to investigate the combined therapeutic effects of pirfenidone (PFD), metformin (MET), and bone marrow-derived mesenchymal stem cells (BM-MSCs) on bleomycin (BLM)-induced pulmonary fibrosis in rats. Methods: Forty-eight Western Albino rats were divided into six groups: normal control, BLM-positive control, and four treatment groups receiving PFD, MET, BM-MSCs, and their combination. Treatments were administered for four weeks starting on day 21 post-BLM instillation. Lung tissues were analyzed for oxidative stress markers, inflammatory cytokines, apoptotic markers, and fibrogenic gene expression. Histopathological changes were assessed using hematoxylin and eosin (H&E) and Masson’s trichrome staining. Results: The combination therapy significantly reduced oxidative stress and inflammatory markers while enhancing antioxidant capacity. It decreased pro-apoptotic Bcl-2-associated X protein (BAX) and increased anti-apoptotic B-cell lymphoma 2 (Bcl-2) levels. Additionally, anti-inflammatory interleukin-10 (IL-10) was elevated, while tumor necrosis factor-alpha (TNF-α) and transforming growth factor-beta 1 (TGF-β1) levels were markedly lowered. Gene expression analysis showed a significant downregulation of matrix metalloproteinase-9 (MMP-9) and collagen type 1 alpha 1 (Col1α1). Histologically, the combination treatment group exhibited minimal fibrosis and inflammation, closely resembling normal lung tissue. Conclusions: The combination of PFD, MET, and BM-MSCs offered superior therapeutic efficacy in treating BLM-induced pulmonary fibrosis compared to individual treatments. This multimodal approach effectively targets oxidative stress, inflammation, apoptosis, and fibrosis, suggesting strong potential for future clinical application.

24 June 2026 in Tissue and Cell
Verified
Journal Article
Closed access
Rabab S. HamadRabab S. Hamad
Rabab S. Hamad
SMSura Akram Mohammed
Sura Akram Mohammed
WHWaseem Ali Hasan
Waseem Ali Hasan
NANorhan Ahmed AbuoHashish
Norhan Ahmed AbuoHashish
SASherin Refat El Afify
Sherin Refat El Afify
Sameh SaberSameh Saber
Sameh Saber